Netherlands-Based Detact Diagnostics Plans Keene, New Hampshire, U.S. Headquarters
05/12/2022
The expansion is in partnership with the Hannah Grimes Center for Entrepreneurship, which provides resources for entrepreneurs and companies in the state’s rural Monadnock Region, and Keene State College, which will provide space for Detact Diagnostics to create a Clinical Laboratory Improvement Amendment or (CLIA)-certified laboratories as well as an expansive internship and employment program.
“With its easily accessible networking opportunities compared to larger markets, plus its life-sciences ecosystem and the support from Hannah Grimes, New Hampshire is the ideal destination for our U.S. expansion,” said Joost Gazendam, CEO of Detact Diagnostics. “From its proximity to the Manchester and Nashua areas, to its affordability, quality of life, and community connectivity, this rural region offers endless benefits that will allow us to continue to grow our company, educate a new generation of professionals and deploy life-changing technology.”
CLIA-certified laboratories are federally regulated sites that test human specimens to diagnose, prevent and treat disease. The lab space to be developed at Keene State College will be used for Detact Diagnostics’ on-site bacterial-detection platforms, which enable healthcare providers and food-processing professionals to detect the presence of virus and bacteria and allow for fast, affordable and precise treatment.
“I am happy to welcome Detact to New Hampshire’s growing life science community,” said New Hampshire Department of Business and Economic Affairs Commissioner Taylor Caswell. “In addition to the world-class technology being researched and implemented in our state, this expansion and partnership with Keene State College further demonstrates the value of our ‘triangle’ strategy (employer-academic center-government) to generate high tech investment statewide.”
The patented Detact Diagnostics platform technology called VIPER (Visualization by Infrared Peptide Reaction) involves the immediate release of a quenched Near Infrared (NIR) molecule from its peptide bond after contact with a specific bacteria/enzyme, which emits NIR-light (NIRL). The amount of light released determines the presence of bacteria or viruses. Due to its speed, precision and sensitivity, even with very diluted samples, the potential of this technology is superior compared to other testing products.
Project Announcements
Kimberly-Clark Expands Aiken County, South Carolina, Distribution Operations
05/04/2025
Aerowerks Plans Gaffney, South Carolina, Manufacturing Operations
05/04/2025
Sweden-Based Troax Group Plans Portland, Tennessee, Manufacturing Operations
05/04/2025
Kimberly-Clark Corporation Plans Warren, Ohio, Manufacturing Operations
05/04/2025
Denmark-Based Novonesis Expands Salem, Virginia, Production Operations
05/04/2025
Polyvlies USA Expands Winston-Salem, North Carolina, Manufacturing Operations
05/04/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024